Advertisement

Topics

Daiichi Pharmaceutical Co., Ltd. Company Profile

05:32 EDT 18th June 2018 | BioPortfolio

This section introduces our corporate information, philanthropic activities, environmental reports and such

Location

14-10, Nihonbashi 3-chome
Chuo-ku
Tokyo
103-8234
Japan

Contact

Phone: 81-3-3272-0611
Fax: 81-3-3272-7348
Email: presdrug2@daiichipharm.co.jp


News Articles [354 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo to restructure vaccines subsidiary

Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance...Read More... The post Daiichi Sankyo to restruct...

Daiichi Sankyo to develop new inflammatory disease drugs

Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years...Read More... The post Daiichi Sankyo to develop new inflammatory disease drugs a...

BRIEF—Hitachi and Daiichi Sankyo reach manufacturing accord

Chūō, Tokyo-based pharmaceutical firm Daiichi Sankyo has awarded Hitachi Chemical a contract to manufacture…

Deals this week: Twist Bioscience, Kangmei Pharmaceutical, Daiichi Sankyo

Twist Bioscience has completed a private placement of shares to raise $50m. The company plans to use part of the...Read More... The post Deals this week: Twist Bioscience, Kangmei Pharmaceutical, Daii...

BRIEF — Daiichi and Kaketsuken end vaccines agreement

Japanese companies Daiichi Sankyo and The Chemo-Sero-Therapeutic Research Institute – known as Kaketsuken…

BRIEF—Daiichi Sankyo US reorganization means 280 job cuts

Japanese pharma major Daiichi Sankyo says it will reorganize its US commercial organization as it continues…

Daiichi taps Hitachi for regenerative medicine manufacturing

The deal will help Daiichi’s investigational candidate harness an accelerated regulatory pathway for regenerative products in Japan.

Daiichi Sankyo reports on results for leukemia candidate

Daiichi Sankyo's quizartinib, a drug being tested in a Phase III trial as a treatment for patients with relapsed or refractor -More- 

Drugs and Medications [285 Associated Drugs and Medications listed on BioPortfolio]

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Emetrol cherry [WellSpring Pharmaceutical Corporation]

Emetrol

Cetirizine hydrochloride [Pharmaceutical Associates, Inc.]

Cetirizine Hydrochloride Syrup

Giltuss total release [Gil Pharmaceutical Corp]

Drug Facts

PubMed Articles [478 Associated PubMed Articles listed on BioPortfolio]

Assessment of medium-term cardiovascular disease risk after Japan's 2011 Fukushima Daiichi nuclear accident: a retrospective analysis.

To assess the medium-term indirect impact of the 2011 Fukushima Daiichi nuclear accident on cardiovascular disease (CVD) risks and to identify whether risk factors for CVD changed after the accident.

Roles of children and their parents in the reduction of radiation risk after the 2011 Fukushima Daiichi Nuclear Power Plant accident.

On March 11, 2011, Japan experienced its largest recorded earthquake with a magnitude of 9.0. The resulting tsunami caused massive damage to the Fukushima Daiichi Nuclear Power Plant reactors, and the...

Long-term outcomes of patients evacuated from hospitals near the Fukushima Daiichi nuclear power plant after the Great East Japan Earthquake.

After the accident of the Fukushima Daiichi nuclear power plant due to the Great East Japan Earthquake in March 2011, the Japanese government issued a mandatory evacuation order for people living with...

Radiocesium contamination in house dust within evacuation areas close to the Fukushima Daiichi nuclear power plant.

Outdoor decontamination efforts have been ongoing since the Fukushima Daiichi nuclear power plant (FDNPP) accident; however, little is known about indoor contamination. Therefore, house dust was sampl...

Pharmaceutical cocrystals as an opportunity to modify drug properties: From the idea to application. A review.

The properties of many drugs which have been available on the pharmaceutical market for a long time still need to be improved. Cocrystals are the solid state drug modification which can improve such p...

Clinical Trials [307 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to th...

Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program

The aim of the project is to evaluate effectiveness of a multidimensional pharmaceutical care plan in improving compliance among elderly polypharmacy users at community pharmacy settings. ...

Companies [1051 Associated Companies listed on BioPortfolio]

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Daiichi Fine Chemical Co., Ltd

Daiichi Fine Chemical Co., Ltd. united the fine chemical business of Daiichi Pharmaceutical Group in October 2001.In the economic and social environment in which changes are expected to accelerate in ...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

Daiichi Pharmaceutical Co., Ltd.

This section introduces our corporate information, philanthropic activities, environmental reports and such

More Information about "Daiichi Pharmaceutical Co., Ltd." on BioPortfolio

We have published hundreds of Daiichi Pharmaceutical Co., Ltd. news stories on BioPortfolio along with dozens of Daiichi Pharmaceutical Co., Ltd. Clinical Trials and PubMed Articles about Daiichi Pharmaceutical Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Daiichi Pharmaceutical Co., Ltd. Companies in our database. You can also find out about relevant Daiichi Pharmaceutical Co., Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record